🏛️ Verified NIH Record • Updated 2026-05-01

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults (NCT05164094)

A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: ModernaTX, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (1 items) and avoid the listed exclusions (6 items).

Location: Medical Affiliated Research Institute — Huntsville, Alabama

Age range: 10 Years to 30 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Has had significant exposure to someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 in the past 14 days prior to the screening visit, if the participant has not been fully vaccinated against COVID-19 at least 14 days prior to the screening visit.
  • Has symptomatic acute or chronic illness requiring ongoing medical or surgical care, to include changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator).
  • Significant, progressive, unstable or uncontrolled clinical condition, including any condition that may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures per investigator judgement.
  • Has a history of myocarditis, and/or pericarditis.
  • Has received or plans to receive any licensed or authorized vaccine, to include COVID-19 vaccines, ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study vaccine injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study vaccine injection. Note: Other inclusion and exclusion criteria may apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (65 Sites)

Showing the first 25 of 65 sites.

  • Medical Affiliated Research Institute — Huntsville, Alabama
  • Smart Cures Clinical Research — Anaheim, California
  • Benchmark Research - Colton - HyperCore - PPDS — Colton, California
  • Fomat Medical Research — Oxnard, California
  • Center For Clinical Trials LLC -Paramount — Paramount, California
  • Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS — Riverside, California
  • Peninsula Research Associates - Headlands Research - PPDS — Rolling Hills, California
  • Velocity Clinical Research - Banning - PPDS — San Bernardino, California
  • Acclaim Clinical Research — San Diego, California
  • California Research Foundation - 4180 Ruffin Rd — San Diego, California
  • Orange County Research Center — Tustin, California
  • CenExel iResearch, LLC — Hollywood, Florida
  • Jacksonville Center For Clinical Research - ERN - PPDS — Jacksonville, Florida
  • iResearch Savannah - CenExel - PPDS — Savannah, Georgia
  • Velocity Clinical Research - Savannah — Savannah, Georgia
  • Clinical Research Atlanta - Headlands - PPDS — Stockbridge, Georgia
  • Velocity Clinical Research — Meridian, Idaho
  • Olivo Medical and Wellness Center — Chicago, Illinois
  • DM Clinical Research — River Forest, Illinois
  • Velocity Clinical Research — Valparaiso, Indiana
  • Velocity Clinical Research - Sioux City — Sioux City, Iowa
  • Alliance for Multispecialty Research, LLC - El Dorado - PPDS — El Dorado, Kansas
  • Johnson County Clin-Trials — Lenexa, Kansas
  • Alliance for Multispecialty Research LLC, East Wichita — Wichita, Kansas
  • Michael W Simon MD, PSC — Lexington, Kentucky

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Epstein-Barr Virus Infection

Explore by condition: All Epstein-Barr Virus Infection clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗